Tikva Allocell Pte Ltd
Muly Tham has a strong background in research, with a focus on studying rare spontaneous self-healing skin tumors and the molecular mechanisms of tumor regression. With experience in various research roles at different organizations, Muly has utilized techniques such as establishment and maintenance of mouse colonies, chemical and UV carcinogenesis, histo-pathological evaluation of tumors, miRNA profiling, tumor initiating cell isolation, culture and transplantation, and animal surgery in their work. Additionally, Muly has a Doctor of Philosophy in Neural stem cell from the National University of Singapore and a Bachelor of Science in Neuroscience from the University of Nottingham.
This person is not in any teams
This person is not in any offices
Tikva Allocell Pte Ltd
Tikva Allocell is a cell therapy company focused on a Second Generation Allogeneic EBV-Specific T cell (ALLO EBVST) platform to target difficult-to-treat cancers. At Tikva Allocell, our mission is to develop safe, effective, readily available and affordable “off-the-shelf” T cell therapies by leveraging excellent safety profile of ALLO EBVST and proprietary technologies that enhance the T cell's performance to treat cancer.